Strategic Focus CereGate is a Munich-based neurotechnology company focused on computer-brain interface solutions and neuromodulation therapy, presenting a potential for enterprise partnerships in neuromodulation platforms and sensory restoration.

Clinical Validation With successful human trials and collaboration with industry partners, CereGate demonstrates credible proof of concept, strengthening the case for clinical deployments and payer discussions.

Funding Momentum Recent funding from Heal Capital and High-Tech Gründerfonds indicates investor confidence and potential for accelerated product development, regulatory progression, and market entry.

Targeted Applications Software platform for neuromodulation programming aimed at gait issues in Parkinson’s and other neurotherapy uses suggests ready-made value propositions for healthcare systems and clinics seeking improved patient outcomes.

Growth Profile Small- to mid-size team with ambitious tech stack and partnerships positions CereGate as an early-stage innovator with opportunities to scale through OEMs, medical device distributors, or hospital networks.